What records are connected here?
- Evidence lanes
- 2
- Source years
- 5
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved6,9Evidence: Smaller human trialsEyes
Thymosin beta-4 is a naturally occurring human peptide recorded in FDA’s substance registry. TB-500, a separate profile, is a short synthetic fragment of it.6 It has been tested as an eye treatment in small randomized trials: in dry eye, its main goals were not met, and in a Phase 3 trial of 18 people with a nerve-related corneal disease, complete healing was more common but not significantly so.7,8 No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists only the TB-500 fragment, and thymosin beta-4 itself is not among the six peptides in HHS’s October 2026 draft policy.6,9,11
| What it is | Human thymosin beta-4, also recorded as TMSB4 and TB4X in FDA’s substance registry.6 |
|---|---|
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists a thymosin beta-4 fragment, TB-500, among withdrawn nominations, but not thymosin beta-4 itself.6,9 |
| Human evidence | Small randomized, placebo-controlled eye trials: one in 72 people with dry eye and a Phase 3 trial in 18 people with neurotrophic keratopathy.7,8 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Thymosin beta-4 is a human peptide that FDA’s substance registry records under names including human thymosin beta-4, TMSB4 and TB4X.6
TB-500, which FDA’s safety-risk page describes as a thymosin beta-4 fragment (LKKTETQ), is a different, much shorter substance with its own profile on this site.9
Trial authors describe it as a regenerative peptide and studied it to promote healing of the surface of the eye.8
The sources reviewed here do not establish its mechanism in people.6,7
In a 2015 Phase 2 trial, 72 people with moderate to severe dry eye were randomized to thymosin beta-4 or placebo for 28 days. Neither main outcome, eye discomfort or staining of the lower cornea, differed significantly, though some secondary measures improved.7
In a 2022 Phase 3 trial in 18 people with neurotrophic keratopathy, a nerve-related corneal disease, the defect healed completely by four weeks in 6 of 10 given thymosin beta-4 and 1 of 8 given placebo, a difference the authors reported as a trend rather than significant.8
ClinicalTrials.gov lists two further Phase 3 dry eye trials (NCT02974907 and NCT03937882) and a Phase 3 neurotrophic keratopathy trial (NCT05555589) as completed in their 2026 registry records, and earlier completed Phase 2 trials in pressure ulcers (NCT00382174) and venous stasis ulcers (NCT00832091). The registry records cited here do not report their findings.1,2,3,4,5
Evidence-strength label: Smaller controlled human trials. How this label is assigned
None of the sources reviewed here reports an approval of thymosin beta-4 by FDA.6,9
FDA’s compounding safety-risk page, current as of April 22, 2026, lists “thymosin beta-4, fragment (LKKTETQ), also known as TB-500” among withdrawn nominations with possible safety risks. It does not list full-length thymosin beta-4.9
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Thymosin beta-4 is not among them; TB-500 is a fragment of it.10,11
Whether it works for any eye disease: the published trials were small, and their main outcomes were not met or did not reach significance.7,8
Whether findings from eye trials say anything about other uses, which these trials did not test.7,8
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Thymosin beta-4: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Thymosin beta-4 are a bounded selection, not every registration or paper about Thymosin beta-4. For the years before Thymosin beta-4 was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Thymosin beta-4 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Thymosin beta-4 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
No FDA approval reported. Small randomized eye trials found that main outcomes were not met or did not reach significance. Thymosin beta-4 is not among the six peptides in HHS’s October 2026 draft policy, which lists the TB-500 fragment.↗↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
No FDA approval reported. Small randomized eye trials found that main outcomes were not met or did not reach significance. Thymosin beta-4 is not among the six peptides in HHS’s October 2026 draft policy, which lists the TB-500 fragment.↗↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 9, 2026
Role of Thymosin Beta 4 in the diagnosis of Nonalcoholic Fatty Liver and its relation to Metabolic Syndrome in Egyptian patients.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Role of Thymosin Beta 4 in the diagnosis of Nonalcoholic Fatty Liver and its relation to Metabolic Syndrome in Egyptian patients.↗Source date November 9, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT05555589↗Source date November 5, 2026Literature metadata · added November 16, 2026
The preliminary study of exosomes derived from thymosin beta 4-treated adipose-derived stem cells in fat grafting.↗Source date October 30, 2026PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
7 of 7 selected trial records include at least one phase value; 7 of 7 include a status value in the retained structured contract.
25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00382174 at 2026-11-16T01:44:56.605Z. Its registry update date was 2010-02-01, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.
PeptideScanner retained ClinicalTrials.gov record NCT00832091 at 2026-11-16T01:44:56.605Z. Its registry update date was 2010-03-30, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.
PeptideScanner retained ClinicalTrials.gov record NCT01387347 at 2026-11-16T01:44:56.605Z. Its registry update date was 2015-07-10, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.
25 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span February 1, 2010 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 35436057 in The Egyptian journal of immunology as Journal Article, with publication-date metadata of 2022-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05555589 at 2026-11-16T01:44:56.605Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.↗
Literature metadata
PubMed lists PMID 36445571 in Genes & genomics as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-11-29 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02974907 at 2026-11-16T01:44:56.605Z. Its registry update date was 2026-10-21, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03937882 at 2026-11-16T01:44:56.605Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.↗
Literature metadata
PubMed lists PMID 41570941 in Peptides as Journal Article, Review, with publication-date metadata of 2026-01-20 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 40816274 in Stem cell reports as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-14 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 12852258 in Vitamins and hormones as Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Review, with publication-date metadata of 2003 (year precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 17495249 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2007-05-10 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 22158707 in Circulation research as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-12-08 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 23052839 in Histochemistry and cell biology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-10-06 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 23711379 in Protein expression and purification as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-05-24 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-beta-4. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
Clinical Ophthalmology · Official source · Source checked November 15, 2026
International Journal of Molecular Sciences · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026